Post-Relapse Survival in Lymphoma Patients (Pts) after Experiencing Therapy Failure Following an Allogeneic Hematopoietic Cell Transplantation (alloHCT)

Narendranath Epperla(University of Utah), Mehdi Hamadani(Medical College of Wisconsin), Parameswaran Hari(Medical College of Wisconsin), Anita D’Souza, Wael Saber(Medical College of Wisconsin), Abraham S. Kanate(HonorHealth), Timothy S. Fenske(Medical College of Wisconsin), Michael Craig(Edith Cowan University), Marcelo C. Pasquini(Cleveland Clinic), Nirav N. Shah(Medical College of Wisconsin), Ariel Kleman(Medical College of Wisconsin), Dheeraj Kodali(West Virginia University)
Transplantation and Cellular Therapy
February 22, 2017
10.1016/j.bbmt.2016.12.097
Cited by 0

Related Papers

ASTCT Consensus Grading for Cytokine Release Syndrome and Neurologic Toxicity Associated with Immune Effector Cells
|Transplantation and Cellular Therapy|2018|3.6k
Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b/2 open-label study
|The Lancet|2021|1.7k
Lenalidomide after Stem-Cell Transplantation for Multiple Myeloma
|New England Journal of Medicine|2012|1.2k
Current Use of and Trends in Hematopoietic Cell Transplantation in the United States
|Transplantation and Cellular Therapy|2020|718
Myeloablative Versus Reduced-Intensity Hematopoietic Cell Transplantation for Acute Myeloid Leukemia and Myelodysplastic Syndromes
|Journal of Clinical Oncology|2017|664